AT&T (NYSE:T): UBS believes that AT&T could acquire the remaining assets of Vodafone in 2014, once the Verizon Wireless holdings sale is completed. The analyst says that a Vodafone acquisition would be accretive, but reaction in AT&T shares could be muted or negative. The firm rates AT&T a Neutral with a $36 price target.
Best Buy (NYSE:BBY): Barclays raised the price target on Best Buy’s shares to $50 from $38 and increased estimates due to continued cost reductions and management’s utilization of floor space. The firm’s 2014 earnings per share estimate goes to $2.75 from $2.65, versus consensus estimates of $2.67. The shares are Overweight rated.
Sarepta Therapeutics (NASDAQ:SRPT): RW Baird believes that the elimination of Prosensa as a potential competitor to Sarepta Therapeutics offsets any increase in risk to its fundamental thesis. The firm believes a drug failure will also open the door in Europe into other exons that previously would be blocked, increasing the potential upside for shareholders. The shares are Outperform rated with a $63 price target.
Salesforce.com (NYSE:CRM): Stephens views the recent announcements from Salesforce.com as reinforcing its thesis that the company’s enterprise positioning is improving. The firm raised its price target for the shares to $65 from $60 and reiterates an Overweight rating on the name.